2. Anti-infection
  3. Bacterial
  4. CyLip-20

CyLip-20 is a cyclic lipopeptide antimicrobial peptide that targets Gram-positive and Gram-negative bacteria. CyLip-20 exhibits low hemolytic activity and mild in vivo toxicity. CyLip-20 disrupts the integrity of bacterial outer membrane, inner membrane and cytoplasmic membrane by binding to bacterial lipopolysaccharide (LPS), triggering membrane permeabilization, depolarization and leakage of intracellular contents, and inhibits bacterial biofilm formation. In animal models, CyLip-20 reduces the bacterial load in skin wounds of mice infected with MRSA, promotes wound healing, decreases the levels of inflammatory cytokines and reduces inflammatory cell infiltration. CyLip-20 can be used in research related to MRSA skin wound infections.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

CyLip-20

CyLip-20 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CyLip-20 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CyLip-20 is a cyclic lipopeptide antimicrobial peptide that targets Gram-positive and Gram-negative bacteria. CyLip-20 exhibits low hemolytic activity and mild in vivo toxicity. CyLip-20 disrupts the integrity of bacterial outer membrane, inner membrane and cytoplasmic membrane by binding to bacterial lipopolysaccharide (LPS), triggering membrane permeabilization, depolarization and leakage of intracellular contents, and inhibits bacterial biofilm formation. In animal models, CyLip-20 reduces the bacterial load in skin wounds of mice infected with MRSA, promotes wound healing, decreases the levels of inflammatory cytokines and reduces inflammatory cell infiltration. CyLip-20 can be used in research related to MRSA skin wound infections[1].

In Vitro

CyLip-20 (4-32 μM; 18-24 h) exhibits broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria, including Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853, with a GMall of 5.19 μM[1].
CyLip-20 (10 mM; 0-48 h) remains highly stable in mouse serum with a half-life exceeding 48 h[1].
CyLip-20 (1 mM; incubated with proteases for 6 h) shows high stability against trypsin and chymotrypsin (0.02-200 μg/mL), and retains antimicrobial activity in both cases[1].
CyLip-20 (1/2×MIC-4×MIC; 24 h) exerts a concentration-dependent inhibitory effect on biofilm formation by Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), and Pseudomonas aeruginosa (P. aeruginosa)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CyLip-20 Related Antibodies

Cell Viability Assay[1]

Cell Line: S. aureus ATCC 25923, B. subtilis ATCC 23857, S. epidermidis ATCC 12228, E. faecalis ATCC 29212, E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, A. baumannii ATCC 19606
Concentration: MIC
Incubation Time: 24 h
Result: Showed MIC values of 4 μM for S. aureus ATCC 25923, B. subtilis ATCC 23857, S. epidermidis ATCC 12228, E. coli ATCC 25922, K. pneumoniae ATCC 700603, P. aeruginosa ATCC 27853, A. baumannii ATCC 19606, and showed a MIC value of 32 μM for E. faecalis ATCC 29212.
Inhibited the biofilm formation in a concentration-dependent manner against S. aureus, E. coli, and P. aeruginosa.
In Vivo

CyLip-20 (2 mg/mL, 10 μL; topical; 6 times at 1 h intervals) effectively reduces MRSA bacterial load, promotes wound healing, and improves tissue repair in MRSA-infected skin wounds of BALB/C mice[1].
CyLip-20 (30-130 mg/kg; i.p.; single dose) has an LD50 of 62.52 mg/kg in male BALB/C mice, showing lower in vivo toxicity than Polymyxin B (HY-149179)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MRSA skin wound infection model in BALB/C mouse (male, 6-8 weeks old, 20 ± 2 g)[1]
Dosage: 2 mg/mL; 10 μL
Administration: topical; 6 times at 1 h intervals; observed the wound healing at days 12.
Result: Reduced MRSA bacterial load at the wound site.
Significantly promoted wound healing, with wound area smaller than model and vancomycin groups by day 4, scabs almost fell off by day 6, wounds almost completely healed by day 8.
Reduced serum TNF-α levels.
Rendered skin tissue structure closest to healthy control with no obvious cell swelling, necrosis, or abnormal proliferation.
Reduced macrophage and neutrophil infiltration at the wound site
Molecular Weight

1544.88

Formula

C78H117N19O14
Sequence

C8-{Dab}-{Dab}-Trp-{d-Tyr}-cyclo(Lys-{Dab}-{Dab}-Trp-{d-Leu}-{d-Leu}-Glu)
Sequence Shortening

C8-{Dab}-{Dab}-W-{d-Tyr}-cyclo(K-{Dab}-{Dab}-W-{d-Leu}-{d-Leu}-E)
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CyLip-20 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CyLip-20CyLip20CyLip 20BacterialE. coliMRSAbacterial lipopolysaccharide (LPS)bacterial inner membraneGram-negative bacteriaS. aureuscytoplasmic membranebacterial outer membraneP. aeruginosaGram-positive bacteriaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CyLip-20
Cat. No.:
HY-P11582
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.